Military psychology : the official journal of the Division of Military Psychology, American Psychological Association
January 1, 2024
Stacey B Armstrong, Yitong Xin, Nathan D Sepeda et al.
19 citations
Among 45 U.S. Special Operations Forces Veterans with risky alcohol use who completed ibogaine and 5-MeO-DMT treatment in Mexico, alcohol use dropped substantially from an average of 7.2 drinks per drinking day before treatment to 3.6 at one month and 4.0 at six months post-treatment. At one month, 24% were abstinent, 33% were non-risky drinkers, and 42% still risky drinkers; by six months, 16% were abstinent, 31% non-risky, and 53% risky. Responders (abstinent or non-risky) showed very large improvements in PTSD symptoms and cognitive functioning compared to non-responders, while demographics did not differ. The findings suggest psychedelic-assisted therapy may help those with complex trauma and alcohol misuse who have not responded to traditional treatments.
BMJ Open
May 1, 2023
Alan K Davis, Adam W Levin, Paul B Nagib et al.
19 citations
Psilocybin-assisted therapy may help treat post-traumatic stress disorder (PTSD), which current treatments often fail to relieve, especially in U.S. military veterans. This open-label pilot study will test two psilocybin doses (15 mg and 25 mg) combined with psychotherapy in 15 veterans with severe, treatment-resistant PTSD. The primary safety outcome tracks adverse events and suicidal ideation; the primary PTSD outcome uses the Clinician Administered PTSD Scale-5. Follow-up continues for 6 months after the second session. Results will be published in a peer-reviewed journal.
Social work
April 1, 2025
Maha N Mian, Jordan Horan, Taweh Hunter et al.
1 citation
Social workers rated SSRI-assisted therapy as significantly more acceptable, appropriate, and feasible than MDMA-assisted therapy for treating adolescents with treatment-resistant PTSD, with medium-to-large effect sizes. Perceptions of MDMA risk were higher among those who read about MDMA-assisted therapy, and greater psychedelic stigma correlated with higher perceived risk of MDMA. However, more psychedelic knowledge was linked to less stigma and lower perceived risk. These findings suggest that social workers' concerns about MDMA-assisted therapy for adolescents may hinder clinical trial recruitment and future implementation.